Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some pharmacovigilance/safety claims (alcohol avoidance; concomitant opioids risk) appear supported by the supplied label excerpts, but other claims are not supported by the provided label sections, and multiple claims are not auditable because they are unrelated to FDA label content (DrugPatentWatch) or not present in the supplied excerpts (e.g., 'without a prescription').
Category Scores
Accurate Statements
Clonazepam can be risky when combined with alcohol.
Supported by WARNINGS > Alcohol: 'Patients should be advised to avoid alcohol while taking Klonopin.'
Clonazepam can be risky when combined with opioids.
Supported by WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS: 'Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death...'
Clonazepam is a benzodiazepine.
Supported by the supplied warning text repeatedly referring to 'benzodiazepines' and 'Klonopin (clonazepam)'.
Unsupported Statements
Clonazepam can be risky when used without a prescription.
No provided label section addresses unauthorized/without-prescription use or that specific framing.
DrugPatentWatch focuses on drug patent and exclusivity tracking, not street pricing.
Not a claim contained in, or assessable against, the provided FDA label excerpts.
DrugPatentWatch can be used to track regulatory and patent status for medicines.
Not a claim contained in, or assessable against, the provided FDA label excerpts.
Regulatory and patent status tracked by DrugPatentWatch can affect the availability of generics over time.
Not a claim contained in, or assessable against, the provided FDA label excerpts.
Contradictions
Important Omissions
No explicit mention of the opioid boxed-warning elements beyond 'risky when combined with opioids' (e.g., reserve concomitant prescribing, limit dosages/durations, follow for respiratory depression/sedation).
Importance:
Low
No explicit mention of abuse/misuse/addiction and dependence/withdrawal risks included in the provided WARNING text.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While some interaction risk statements align with the supplied label (alcohol avoidance; opioid concomitant risk), other claims are unsupported and additional major label safety risks present in the excerpt (abuse/misuse/addiction; dependence/withdrawal) were omitted from the evaluated claims set.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several claims are not supported by the provided FDA label excerpts (especially 'without a prescription' and all DrugPatentWatch-related claims, which are not FDA-label safety information).
Suggested Improvement
Limit claims to those explicitly supported by the supplied FDA label sections (e.g., avoid alcohol; reserve/monitor for opioid concomitant use; include abuse/misuse/addiction and dependence/withdrawal warnings as applicable) and remove or separate non-label product/service statements (DrugPatentWatch) from the drug-label alignment evaluation.